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Evaluating the Efficiency of Using
Second-Trimester Nasal Bone Hypoplasia
as a Single or a Combined Marker 
for Fetal Aneuploidy
Anthony O. Odibo, MD, FRCOG, Harish M. Sehdev, MD,
Laura Sproat, MD, Claudia Parra, MD, Linda Odibo, BSc, RN,
Linda Dunn, MD, George A. Macones, MD, MSCE
Objective. Although second-trimester nasal bone (NB) hypoplasia has been associated with fetal ane-
uploidy, its role as a single marker is still uncertain. Our objective was to evaluate the efficiency of NB
hypoplasia as an independent marker for fetal aneuploidy. Methods. This was a prospective cohort
study of women undergoing an anatomic survey between 16 and 22 weeks’ gestation. The fetal NB
and other markers of fetal aneuploidy, including nuchal fold, femur and humeral lengths, choroid
plexus cysts, major fetal anomalies, echogenic bowel, pyelectasis, and hypoplastic fifth digits, were
evaluated. Nasal bone hypoplasia was defined either as an absent NB or by a ratio of the biparietal
diameter to NB. Fetuses or infants with fetal aneuploidy were compared with those without for the
presence of NB hypoplasia either as a single marker or in the presence of other markers for aneuploidy.
Results. Of 2885 women evaluated, NB measurements were obtained in 2465 (85%). There were 35
(1.4%) cases with fetal aneuploidy. The sensitivity and specificity of a single NB in detecting Down syn-
drome varied from 23% to 64% and 57% to 99%, respectively, depending on the definition of NB
hypoplasia used. There was an improvement in the efficiency of using the NB when combined with
other markers, with sensitivity and specificity increasing from 59% to 82% and 74% to 87%, respec-
tively. Conclusions. Nasal bone hypoplasia is a marker for fetal aneuploidy. The combination of the NB
with other makers was associated with an improvement in detection of fetal aneuploidy. Key words:
aneuploidy; Down syndrome; hypoplasia; nasal bone. 
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everal studies have suggested that an absent fetal
nasal bone (NB) or NB hypoplasia is a marker for
aneuploidy in the first and second trimesters of
pregnancy.1–11 These studies have used several defi-
nitions of NB hypoplasia making generalizability problem-
atic. In a recent study limited to women having prenatal
diagnosis, we reported that a ratio of the biparietal diame-
ter (BPD) to NB of greater than 11.0 was the best definition
of NB hypoplasia associated with aneuploidy.12
It is, however, still uncertain how the NB performs as a
single marker for fetal aneuploidy compared with when
combined with other proven markers of aneuploidy. This
current study aimed to evaluate the efficiency of using
NB hypoplasia as a single marker for fetal aneuploidy.




This was a prospective cohort study of women
undergoing an anatomic survey between 16 and
22 weeks’ gestation over 18 months. The study
patients were identified consecutively. The fetal
NB and other markers of fetal aneuploidy, includ-
ing nuchal fold, femur and humeral lengths,
choroid plexus cysts, major fetal anomalies,
echogenic bowel, pyelectasis, and hypoplastic
fifth digits, were evaluated. Approval from the
institutional review boards of all study centers was
obtained.
The fetal NB was assessed as previously
described by Sonek and Nicolaides.2 The facial
profile of the fetus was obtained in the midsagit-
tal plane and by rocking the transducer side-
ways. The angle of insonation was maintained at
45° or 135°. The NB is seen as a triangular
echogenic structure in this view. All sonographic
evaluations were performed by experienced
American Registry for Diagnostic Medical
Sonography–certified sonographers, with train-
ing in first-trimester screening ultrasound.
Several definitions of NB hypoplasia, including
an absent NB and BPD/NB ratios of greater than
9, 10, 11, and 12, were evaluated. Short femur and
humeral lengths were defined as measurements
of less than 0.91 and 0.89 compared with the
expected measurements for the gestational age,
respectively.13 Fetuses or infants with fetal aneu-
ploidy were compared with those without for the
presence of NB hypoplasia either as a single
marker or in the presence of other markers. Fetal
karyotypes were confirmed either by chromoso-
mal analysis when available or by neonatal exam-
ination.
Statistical analysis was performed with the χ2
test for categorical variables and the Student t
test for continuous variables. The primary out-
come was the association between NB and
fetal aneuploidy. All analyses were performed
with Stata version 8.0 (StataCorp, College
Station, TX).
Results 
During the study period, 2885 women were eval-
uated, and NB measurements were obtained in
2465 (85%). The demographic characteristics for
our study population are shown in Table 1. The
mean maternal age ± SD was 30.2 ± 6.7 years, and
50% of the study population were white. There
were 35 (1.4%) cases with fetal aneuploidy, with
most having trisomy 21 (Table 2).
The efficiency of using NB hypoplasia to screen
for trisomy 21 as a single maker is shown in Table
3. Although a BPD/NB ratio of greater than 9 had
the best sensitivity, an absent NB had the best
specificity of 99%. The information in Table 3 was
used to construct a receiver operating character-
istic (ROC) curve, which reveals the optimal
tradeoff between sensitivity and specificity to be
the point correlating with the use of a BPD/NB
ratio of greater than 11.0 (Figure 1). The specifici-
ty of using a BPD/NB ratio of greater than 11 to
screen for Down syndrome is 85% (95% confi-
dence interval [CI], 84%–86%) compared with
using a BPD/NB ratio of greater than 12, with
specificity of 93% (95% CI, 92%–94%). The
nonoverlapping CIs indicate a statistically signif-
icant difference in specificity with these two NB
criteria. Conversely, the sensitivity of a ratio of
greater than 11 was 59% (95% CI, 36%–79%), and
a ratio of greater than 12 had sensitivity of 41%
(95% CI, 27%–64%), the overlapping CIs indicat-
ing statistical nonsignificance. An absent NB was
associated with the highest positive predictive
value and positive likelihood ratio.
The efficiency of the NB when combined with
other markers (as part of a genetic sonogram) is
depicted in Table 4. The sensitivity and specifici-
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Table 1. Demographics of Subjects Evaluated for NB
(n = 2885)
Characteristic Value






Table 2. Types of Chromosomal Anomalies Detected
in the Study Population (n = 2885)
Abnormality n (%)
Abnormal karyotypes 35 (1.2)
Trisomy 21 22 (63)
Trisomy 18 7 (20)
Triploidy 1 (3)
45 XO 2 (6)
Others 3 (8)
J Ultrasound Med 2006; 25:437–441
ty for trisomy 21 with the use of other markers
without adding the NB were 45% (95% CI,
24%–68%) and 87% (95% CI, 86%–88%), respec-
tively.  When the NB (using a BPD/NB ratio of
>11 to define NB hypoplasia) was combined with
other markers, the sensitivity and specificity for
detection of trisomy 21 were 82% (95% CI,
60%–95%) and 74% (95% CI, 72%–76%), respec-
tively. The use of an absent NB and other mark-
ers was associated with a modest increase in
sensitivity but maintained the same specificity.
The likelihood ratios for positive or negative NB
hypoplasia in predicting trisomy 21 as a single
finding or combined with other markers are also
shown in Table 4. Figure 2 is an ROC curve
depicting the efficiency of combining NB with
other markers. The optimal threshold point for
this curve corresponds to the use of a BPD/NB
ratio of greater than 11 combined with other
markers.
Table 5 shows the screening performance of
using  NB as a single marker or in combination
with other markers to screen for all aneuploidy.
The sensitivity and specificity were lower com-
pared with screening for Down syndrome only.
An absent NB was seen in a case of Edward syn-
drome and when a BPD/NB ratio of greater than
11 was used as the definition of NB hypoplasia;
1 additional case of Edward syndrome was
detected. There was only 1 case of Turner syn-
drome with a BPD/NB ratio of greater than 11.
Discussion
Our findings confirm the association between
NB hypoplasia and aneuploidy. This association
was stronger with trisomy 21 compared with
other types of aneuploidy. In addition, our
results suggest the NB to have modest efficiency
as a single maker for trisomy 21. The finding of
an absent NB when single was highly specific for
detecting Down syndrome, and the likelihood
ratio of 23 suggests that this is one of the most
powerful markers in the second trimester.
However, to improve second-trimester detection
of Down syndrome, the goal will be to maximize
the sensitivity of a combination of markers while
maintaining reasonable specificity. Our findings
using the ROC curve (Figure 2) suggest that the
use of a BPD/NB ratio of greater than 11 could
achieve this goal. The lower specificity, however,
indicates the need for a stricter definition of NB
hypoplasia, such as a BPD/NB ratio of greater
than 12.
The specificity of a BPD/NB ratio of greater
than 11 in this study is lower compared with
that given in previous reports on the association
between NB hypoplasia and Down syndrome.9,11,12
One possible reason for our lower specificity
could be the higher percentage of black patients
in our study population compared with those in
previous reports.14 The small study population
was, however, insufficient to perform a stratified
analysis by race or ethnicity. The specificity of an
J Ultrasound Med 2006; 25:437–441 439
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Table 3. Relationship Between NB and Down Syndrome According to Various Definitions of NB Hypoplasia
Parameter Absent NB BPD/NB >9 BPD/NB >10 BPD/NB >11 BPD/NB >12
Sensitivity, n (%) 5/22 (23) 14/22 (64) 13/22 (59) 13/22 (59) 9/22 (41)
Specificity, n (%) 2433/2446 (99) 1382/2423 (57) 1783/2423 (74) 2061/2423 (85) 2262/2423 (93)
PPV, n (%) 5/18 (28) 14/1055 (1) 13/653 (2) 13/375 (3) 9/170 (5)
NPV, n (%) 2433/2450 (99) 1382/1390 (99) 1783/1792 (99) 2061/2070 (99) 2262/2275 (99)
LR+ 23 1.5 2.3 3.9 5.9
LR– 0.8 0.6 0.6 0.5 0.6
LR+ and LR– indicate positive and negative likelihood ratios; NPV, negative predictive value; and PPV, positive predictive
value.
Figure 1. Receiver operating characteristic curve of model using
different definitions of NB hypoplasia only for detection of
Down syndrome.
absent NB is, however, similar to those previous-
ly reported. In addition, the sensitivity values of
other genetic markers for predicting Down syn-
drome reported in this study are lower than
those previously reported from most centers
evaluating second-trimester genetic sono-
grams.15 Previous studies have reported sensitiv-
ity ranging from 67% to 93%, compared with 45%
in this study population.15 Possible explanations
for this observation include differences in study
populations, methods, sample sizes, and gesta-
tional ages at screening. The wide CI around the
sensitivity for other markers seen in this study
(24%–68%) would suggest that the small number
of fetuses with Down syndrome may be respon-
sible for the variation. Because many studies do
not report the CI around their point estimate for
the accuracy of these markers, it is difficult to
compare these reports with ours. Consequently,
in centers that have had higher accuracy with the
use of the genetic sonogram, the addition of the
NB could result in a greater improvement in the
prediction of Down syndrome than what we
have reported in this study.
These findings are important in counseling
patients for whom NB hypoplasia is the only
finding on sonography regarding the utility of a
diagnostic test such as amniocentesis. The
importance of these findings will, however, be
influenced by the a priori risk of the patient. In
women with an a priori risk of less than 1 per
1500, the positive likelihood ratio of 3.9 for NB
hypoplasia as a single marker (using a BPD/NB
ratio of >11) and risk of Down syndrome may not
appreciably affect their posttest (sonography)
risk. Conversely, for a patient with an a priori risk
of greater than 1 per 1500, the presence of NB
hypoplasia as a single marker could lead to an
appreciable change in her a priori risk, resulting
in acceptance of a diagnostic test. The finding of
an absent NB as the only finding is, however, sig-
nificant, and our results would suggest that rec-
ommending an invasive test for this indication is
reasonable. When combined with other markers
for fetal aneuploidy, the performance of NB
hypoplasia in detecting aneuploidy improved.
This was more significant for trisomy 21 com-
pared with all types of aneuploidy.
This study has some limitations, including a
small sample size and the associated difficulty
with performing a stratified analysis based on
the gestational age at screening. For example, it
was not possible to stratify our groups into those
seen before 18 weeks and those after 18 weeks.
Our study population also included a consider-
able number of high-risk women, accounting for
the high prevalence of aneuploidy within this
small cohort. This may be a reflection that most
of our patients are high-risk women being eval-
uated in maternal-fetal medicine units. The
results are not affected by any selection bias
because all patients were identified consecutive-
440 J Ultrasound Med 2006; 25:437–441
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Table 4. Efficiency of Including NB Hypoplasia With Other Second-Trimester Markers for Down Syndrome 
Other Markers Absent NB + Other BPD/NB >11 + Other BPD/NB >12 + Other
Parameter Only Markers Markers Markers
Sensitivity, n (%) 10/22 (45) 13/22 (59) 18/22 (82) 15/22 (68)
Specificity, n (%) 2109/2423 (87) 2116/2423 (87) 1798/2423 (74) 1968/2423 (81)
PPV, n (%) 10/324 (3) 13/343(3) 18/643 (3) 15/470 (3)
NPV, n (%) 2109/2121 (99) 2116/2125 (99) 1798/1802 (99) 1968/1975 (99)
LR+ 3.5 3.9 3.2 3.6
LR– 0.6 0.5 0.2 0.4
LR+ and LR– indicate positive and negative likelihood ratios; NPV, negative predictive value; and PPV, positive predictive value.
Figure 2. Receiver operating characteristic curve of model using
combinations of different definitions of NB hypoplasia and other
markers for detection of Down syndrome.
ly. Consequently, our findings may not be gener-
alizable to a low-risk population. Finally, we were
unable to obtain adequate facial profiles in 15%
of our study population because of fetal position.
It is impossible to determine how this could have
affected our results. If the NB is to be used as a
marker for aneuploidy, then greater efforts at
obtaining optimal facial profiles cannot be
overemphasized.
This study corroborates the findings of previ-
ous reports associating NB hypoplasia and fetal
aneuploidy and suggests that such an associa-
tion could be important when this finding is a
single marker. Future larger studies addressing
this issue and evaluating the best definition of
NB hypoplasia are urgently needed.
References
1. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K.
Absence of nasal bone in fetuses with trisomy 21 at 11–14
weeks gestation: an observational study. Lancet 2001;
358:1665–1667.
2. Sonek JD, Nicolaides KH. Prenatal ultrasonographic diag-
nosis of nasal bone abnormalities in three fetuses with
Down syndrome. Am J Obstet Gynecol 2002; 186:139–
141.
3. Otano L, Aiello H, Igarzabal L, Matayoshi T, Gadow EC.
Association between first trimester absence of fetal nasal
bone on ultrasound and Down syndrome. Prenat Diagn
2002; 22:930–932.
4. Zoppi MA, Ibba RM, Axiana C, Floris M, Manca F, Monni
G. Absence of fetal nasal bone and aneuploidies at first-
trimester nuchal translucency in unselected pregnancies.
Prenat Diagn 2003; 23:496–500.
5. Orlandi F, Bilardo CM, Campogrande M, et al.
Measurement of nasal bone length at 11–14 weeks of
pregnancy and its potential role in Down syndrome risk
assessment. Ultrasound Obstet Gynecol 2003; 22:36–39.
6. Viora E, Masturzo B, Errante G, Sciarrone A, Bastonero S,
Campogrande M. Ultrasound evaluation of fetal nasal
bone at 11–14 weeks in a consecutive series of 1906 fetus-
es. Prenat Diagn 2003; 23:784–787.
7. Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides
KH. Absent nasal bone at 11–14 weeks’ gestation and
chromosomal defects. Ultrasound Obstet Gynecol 2003;
22:31–35.
8. Vintzileos A, Walters C, Yeo L. Absent nasal bone in the
prenatal detection of trisomy 21 in a high-risk population.
Obstet Gynecol 2003; 101:905–908.
9. Bromley B, Lieberman E, Shipp TD, Benacerraf B. Fetal
nasal bone length: a marker for Down syndrome in the
second trimester. J Ultrasound Med 2002; 21:1387–1394.
10. Bunduki V, Ruano R, Miguelez J, Yoshizaki CT, Kahhale S,
Zugaib M. Fetal nasal bone length: reference range and
clinical application in ultrasound screening for trisomy 21.
Ultrasound Obstet Gynecol 2003; 21:156–160.
11. Cicero S, Sonek JD, Mckenna DS, Croom CS, Johnson L,
Nicolaides KH. Nasal bone hypoplasia in trisomy 21 at
15–22 weeks’ gestation. Ultrasound Obstet Gynecol 2003;
21:15–18.
12. Odibo AO, Sehdev HM, Dunn L, McDonald R, Macones
GA. The association between fetal nasal bone hypoplasia
and aneuploidy. Obstet Gynecol 2004; 104:1229–1233.
13. Nyberg DA, Resta RG, Luthy DA, Hickok DE, Michelle A.
Humerus and femur length shortening in the detection of
Down’s syndrome. Am J Obstet Gynecol 1993; 168:
534–538.
14. Zelop CM, Milewski E, Brault K, Benn P, Borgida AF, Egan
JFX. Variation of fetal nasal bone length in second-
trimester fetuses according to race and ethnicity. 
J Ultrasound Med 2005; 24:1487–1489.
15. Bahado-Singh RO, Oz UA, Mendilcioglu I, Mahoney MJ.
The mid-trimester genetic sonogram. Semin Perinatol
2005; 29:209–214.
J Ultrasound Med 2006; 25:437–441 441
Odibo et al
Table 5. Relationship Between NB as a Single Marker, Combinations With Other Markers, and All Aneuploidy
Characteristic Sens, n (%) Spec, n (%) PPV, n (%) NPV, n (%) LR+ LR–
Absent NB 6/35 (17) 2421/2433 (99) 6/18 (33) 2450/2468 (99) 17 0.83
BPD/NB >11 16/35 (46) 2051/2410 (85) 16/375 (4) 2051/2070 (99) 3.1 0.63
BPD/NB >12 10/35 (29) 2250/2410 (93) 10/170 (6) 2250/2275 (99) 4.1 0.76
Other markers only 16/35 (46) 2102/2410 (87) 16/324 (5) 2102/2121 (99) 3.5 0.62
Absent NB + other 19/35 (54) 2109/2433 (87) 19/343 (6) 2109/2125 (99) 4.2 0.53
markers
BPD/NB >11 + other 25/35 (71) 1792/2410 (74) 25/643 (4) 1792/1802 (99) 2.7 0.39
markers
BPD/NB>12 + other 21/35 (60) 1961/2410 (81) 21/470 (4) 1961/1975 (99) 3.2 0.49
markers
LR+ and LR– indicate positive and negative likelihood ratios; NPV, negative predictive value; PPV, positive predictive
value; Sens, sensitivity; and Spec, specificity.
